Physician profile
Thomas D Jones
NPI 1750383030
$588.94
in general payments reported to CMS, 2019-2025
16 companies · $34.06 in 2025
The $34.06 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.47 · 2020: $166 · 2021: $185 · 2022: $96.04 · 2023: $17.87 · 2025: $34.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $51.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $51.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $171.91 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $71.50 | 2019-2021 | |
| Abbott Laboratories | $63.78 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $53.91 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $31.97 | 2019 | |
| Lilly USA, LLC | $26.81 | 2019-2020 | |
| Genentech USA, INC. | $20.39 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.17 | 2021 | |
| Mylan Specialty L.P. | $19.27 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.86 | 2020 | |
| Daiichi Sankyo INC. | $17.48 | 2019 | |
| Novo Nordisk INC | $16.90 | 2021 | |
| Adlon Therapeutics L.P. | $16.78 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.01 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.71 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.